The acquisition of global rights to the GEAR™ Cell Therapy Platform and the formation of GEAR Therapeutics positions Coeptis Therapeutics to advance in the precision immuno-oncology field. This strategic move is likely to enhance their pipeline and attract investor interest, potentially driving the stock price up in the short term.